Ramucirumab + Icrucumab + mFOLFOX-6
Phase 2Completed 1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Colon Cancer
Conditions
Colon Cancer, Rectal Cancer
Trial Timeline
Aug 1, 2010 → Dec 1, 2013
NCT ID
NCT01111604About Ramucirumab + Icrucumab + mFOLFOX-6
Ramucirumab + Icrucumab + mFOLFOX-6 is a phase 2 stage product being developed by Eli Lilly for Colon Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT01111604. Target conditions include Colon Cancer, Rectal Cancer.
What happened to similar drugs?
4 of 14 similar drugs in Colon Cancer were approved
Approved (4) Terminated (5) Active (6)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01111604 | Phase 2 | Completed |
Competing Products
20 competing products in Colon Cancer